STOCK TITAN

Elite Pharmaceuticals, Inc. - ELTP STOCK NEWS

Welcome to our dedicated news page for Elite Pharmaceuticals (Ticker: ELTP), a resource for investors and traders seeking the latest updates and insights on Elite Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Elite Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Elite Pharmaceuticals's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-25%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20%
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
Elite Pharmaceuticals, Inc.

OTC:ELTP

ELTP Rankings

ELTP Stock Data

142.49M
797.53M
22.23%
2.16%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Northvale

About ELTP

elite pharmaceuticals, inc. develops oral sustained and controlled release products. elite's strategy includes assisting partner companies in the life cycle management of products, to improve off-patent drug products, and developing generic versions of controlled release drug products with high barriers to entry. elite has four anda products partnered with tagi pharma; one anda has launched, two andas are in the process of a manufacturing site transfer and an additional anda is currently under review by the fda. elite also manufactures lodrane d® and receives royalties for lodrane d®, an allergy product partnered with ecr pharmaceuticals (“ecr”), a wholly owned subsidiary of hi-tech pharmacal (“hi-tech”). elite’s lead pipeline products, eli-216, a once-daily abuse resistant oxycodone, and eli-154, a once-daily oxycodone, are novel sustained release oral formulations of opioids for the treatment of chronic pain, which address two of the limitations of existing oral opioids: the provisio